New heart drug candidate HRS-1893 tested in healthy people for first time

NCT ID NCT07033455

Completed Knowledge-focused Sponsor: Atridia Pty Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a single oral dose of HRS-1893 in 20 healthy white male volunteers to see how the body processes the drug and whether it is safe. The study is a first step toward potentially treating hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Because it only involved healthy people and measured drug levels and side effects, it does not yet show if the drug helps the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1893
What this could lead to: If successful, this early study could pave the way for larger trials testing HRS-1893 as a possible treatment for hypertrophic cardiomyopathy.
What could go wrong: This is a very early Phase 1 trial with only 20 healthy people, not patients. It only looks at safety and drug processing, not whether the drug works for the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Locations

Linear Clinical Research

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.